Marta Rybczynski

News

Comparing the Cost-Effectiveness of First-Line Treatments of Chronic Lymphocytic Leukemia

05/11/2022

When compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies may be associated with less health benefits at higher cost, and that the targeted therapies achieve greater benefits at higher cost.

When compared with...

05/11/2022

Journal of Clinical Pathways

News

Existing Value Assessment Frameworks Vary in Defining and Measuring Value in Health Care

02/14/2022

Marta Rybczynski ;

Study findings show substantial variation in defining and measuring value among existing value assessment frameworks in health care.

Study findings show substantial...

02/14/2022

Journal of Clinical Pathways

Conference Coverage

Improving Survival and Managing Costs in NSCLC Using Clinical Care Pathways

10/01/2021

Marta Rybczynski ;

Mark Socinski, MD, discussed the current and ever-evolving treatment landscape of NSCLC and the development and implementation of optimal clinical pathways in this complex disease.

Mark Socinski, MD, discussed the...

10/01/2021

Clinical Pathways

News

Real-World Adoption of Bevacizumab Biosimilar for Metastatic Colorectal Cancer

03/15/2022

Marta Rybczynski ;

Real-world evidence from US community-based oncology practices supports the adoption of bevacizumab-awwb for treating patients with metastatic colorectal cancer.

Real-world evidence from US...

03/15/2022

Journal of Clinical Pathways

News

Real-World Utilization of and Spending on New Targeted Cancer Drugs in the United States

11/03/2021

Marta Rybczynski ;

A real-world study suggests that cancer drugs without documented OS benefits are increasingly adopted in the health system, accounting for substantial spending.

A real-world study suggests that...

11/03/2021

Journal of Clinical Pathways

News

Survival Outcomes Among Patients With Mantle Cell Lymphoma Treated With Bruton Tyrosine Kinase Inhibitors

03/29/2022

Marta Rybczynski ;

A population-based cohort analysis on patients who were diagnosed with mantle cell lymphoma found that overall survival and lymphoma-specific survival may improve with BTK inhibitors.

A population-based cohort...

03/29/2022

Journal of Clinical Pathways

News

Changes in Frontline Therapy Associated With Improved Survival Outcomes Among Patients With MCL

02/18/2022

Marta Rybczynski ;

Study findings provide real-world evidence for improved outcomes with the evolving frontline pattern of care in patients with MCL.

Study findings provide...

02/18/2022

Journal of Clinical Pathways

Conference Coverage

Designing Patient-Centered Pathways at Kaiser Permanente

10/02/2021

Marta Rybczynski ;

Mishellene McKinney, MHA, RN, OCN, discusses how Kaiser Permanente is using Human Centered Design to inform cancer care delivery and survivorship pathway design.

Mishellene McKinney, MHA, RN,...

10/02/2021

Clinical Pathways

Conference Coverage

Addressing Disparities in Cancer Health, Equity, and Outcomes

03/29/2022

Marta Rybczynski ;

A panel at the 2022 Community Oncology Conference discussed how their programs address disparities in cancer care and access to cancer care.

A panel at the 2022 Community...

03/29/2022

Journal of Clinical Pathways

News

Comparing Consolidation and Maintenance vs Maintenance Alone for Newly Diagnosed MM

11/08/2021

Marta Rybczynski ;

Consolidation treatment with bortezomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance may improve PFS for newly diagnosed MM, compared to maintenance alone.

Consolidation treatment with...

11/08/2021

Journal of Clinical Pathways